Beyond the investigation of the EGFR gene, our method can be adapted to assess other molecular targets (e.g. HER2 [21]), and to analyze cancer cells in other cytological samples, where the low percentage of tumor cells limits the genomic analyses by current methods. This evidence concerns the gene EGFR and neoplasm.